Eyepoint Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
EYPT Nasdaq 2834 https://eyepointpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eyepoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 16th, 2024 11:00 am
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists - Apr 2nd, 2024 11:00 am
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22% - Mar 9th, 2024 1:32 pm
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript - Mar 8th, 2024 2:31 pm
EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations - Mar 8th, 2024 10:28 am
Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call - Mar 8th, 2024 2:39 am
EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023 - Mar 7th, 2024 6:25 pm
Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics - Mar 7th, 2024 2:30 pm
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments - Mar 7th, 2024 12:00 pm
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer - Mar 4th, 2024 12:00 pm
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know - Feb 29th, 2024 3:00 pm
Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going - Feb 29th, 2024 1:50 pm
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 - Feb 29th, 2024 12:00 pm
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - Feb 27th, 2024 12:00 pm
Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice - Feb 15th, 2024 5:00 pm
Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet - Feb 13th, 2024 2:55 pm
Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength - Feb 13th, 2024 1:50 pm
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration - Feb 3rd, 2024 9:20 pm
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - Jan 31st, 2024 12:00 pm
EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares - Jan 30th, 2024 4:02 am